Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17762894 | 0.85 | SIRT2 (0.48) | TRPV1CFTRCYP2D6SIRT2CYP3A4 | |
| SCHEMBL23363361 | 0.83 | TRPV1 (0.56) | TRPV1CFTRCYP2D6CYP3A4 | |
| SCHEMBL23363387 | 0.83 | TRPV1 (0.46) | TRPV1SIRT2CYP3A4 | |
| SCHEMBL2318940 | 0.76 | CFTR (0.61) | TRPV1CFTRCYP2D6CYP3A4 | |
| SCHEMBL16334996 | 0.75 | HTR2C (0.34) | — | |
| SCHEMBL9091707 | 0.73 | TLR3 (0.43) | TRPV1 | |
| SCHEMBL619019 | 0.73 | HDAC3 (0.43) | TRPV1 | |
| SCHEMBL16381656 | 0.72 | HTR2C (0.33) | — | |
| SCHEMBL23363272 | 0.70 | TRPV1 (0.50) | TRPV1CFTRCYP2D6CYP3A4 | |
| SCHEMBL23363355 | 0.69 | TRPV1 (0.52) | TRPV1CFTRCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| EP-3013810-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | Lupin Limited (IN) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | TRPV1 30/4885CFTR 251/4885CYP2D6 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.